J. Hurov

发表

Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis.

L. Cantley, M. Korpal, Jinghang Zhang, 2006, Blood.

GPAT3 and GPAT4 are regulated by insulin-stimulated phosphorylation and play distinct roles in adipogenesis[S]

Dongmei Li, R. Gimeno, Dandan Shan, 2010, Journal of Lipid Research.

Targeting metabolic changes in cancer: novel therapeutic approaches.

E. Bobrovnikova-Marjon, J. Hurov, 2014, Annual review of medicine.

Conference of European Comparative Endocrinologists

S. Schlatt, J. Hurov, Acad Sci, 2004 .

Absence of Apparent Phenotype in Mice Lacking Cdc25C Protein Phosphatase

H. Piwnica-Worms, L. White, T. Woodford-Thomas, 2001, Molecular and Cellular Biology.

Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors

John M. Asara, George Poulogiannis, Brooke M. Emerling, 2013, Cell.

Loss of Par-1a/MARK3/C-TAK1 Kinase Leads to Reduced Adiposity, Resistance to Hepatic Steatosis, and Defective Gluconeogenesis

Robert E. Schmidt, Jochen K. Lennerz, Robert W. Gereau, 2010, Molecular and Cellular Biology.

Mesenchymal Phenotype Predisposes Lung Cancer Cells to Impaired Proliferation and Redox Stress in Response to Glutaminase Inhibition

Abhishek K. Jha, S. Choe, S. Gross, 2014, Cancer & Metabolism.

Immune System Dysfunction and Autoimmune Disease in Mice Lacking Emk (Par-1) Protein Kinase

H. Piwnica-Worms, K. Murphy, C. Zmasek, 2001, Molecular and Cellular Biology.

The Par-1/MARK Family of Protein Kinases: From Polarity to Metabolism

H. Piwnica-Worms, J. Hurov, 2007, Cell cycle.

Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo

G. Shulman, L. Cantley, J. Lennerz, 2007, Proceedings of the National Academy of Sciences.

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

I. Flinn, R. Collins, S. Choe, 2016 .

Action at a distance: allostery and the development of drugs to target cancer cell metabolism.

B. Delabarre, Giovanni Cianchetta, Stuart Murray, 2014, Chemistry & biology.

Full-length human glutaminase in complex with an allosteric inhibitor.

Abhishek K. Jha, S. Gross, B. Delabarre, 2011, Biochemistry.

Atypical PKC Phosphorylates PAR-1 Kinases to Regulate Localization and Activity

H. Piwnica-Worms, J. L. Watkins, J. Hurov, 2004, Current Biology.

Roadmap for the Emerging Field of Cancer Neuroscience

D. Hanahan, Ádám Kepecs, A. Lloyd, 2020, Cell.

Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase

G. Lenz, S. Choe, K. Marks, 2020, Molecular Cancer Therapeutics.

Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition

Abhishek K. Jha, S. Choe, S. Gross, 2014, Cancer & Metabolism.

Abstract 7: LKB1 deficiency is associated with a unique metabolic signature in Kras mutant non-small cell lung cancer (NSCLC)

J. Engelman, C. Benes, J. Hurov, 2016 .